• Submit to Pharmaceuticals Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• For Librarians
• About
• Open Access Policy

• Abstract
• Full-Text HTML
• Full-Text PDF [145 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Corbett, A
• Williams, G
• Ballard, C
• [+] on Google Scholar
• Corbett, A
• Williams, G
• Ballard, C
• [+] on PubMed
• Corbett, A
• Williams, G
• Ballard, C

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter
• More services

Open AccessThis article is

• freely available
• re-usable

Pharmaceuticals 2013, 6(10), 1304-1321; doi:10.3390/ph6101304

Review

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Anne Corbett, Gareth Williams and Clive Ballard *

Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College London, London SE1 1UL, UK

* Author to whom correspondence should be addressed.

Received: 17 September 2013; in revised form: 6 October 2013 / Accepted: 8 October 2013 / Published: 11 October 2013

(This article belongs to the Special Issue Drug Repositioning)

Download PDF Full-Text [145 KB, uploaded 11 October 2013 14:30 CEST]

Abstract: Alzheimer’s Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.

Keywords: Alzheimer’s; repositioning; treatment; drug

Article Statistics

Citations to this Article

Cite This Article